Transgenic mice containing mGluR7 metabotropic glutamate receptor gene disruptions
OwnerKeith Allen, Russell Phillipsinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present disclosure provides transgenic mice comprising mutations in an mGluR7 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
Claims14
A transgenic mouse whose genome comprises a homozygous disruption of the endogenous mGluR7 metabotropic glutamate receptor gene, wherein said mouse exhibits a phenotypic abnormality relative to a wild-type control mouse.
A targeting construct comprising:
- a. a first polynucleotide sequence homologous to at least a first portion of the endogenous mGluR7 gene;
- b. a second polynucleotide sequence homologous to at least a second portion of the mGluR7 gene;
- and
- c. a gene encoding a selectable marker located between the first and second polynucleotide sequences.
A transgenic mouse whose genome comprises a disruption in the endogenous mGluR7 gene, wherein said gene encodes for mRNA corresponding to the cDNA sequence of SEQ ID NO:
- 1, and wherein said disruption comprises replacement of nucleotides 448 to 739 of SEQ ID NO:
- 1 with a LacZ-Neo cassette.
A transgenic mouse whose genome comprises a null allele of the endogenous mGluR7 gene.
Dependencies are inferred from the claim text.